欧洲委员会授予MolMed公司的用于治疗肝细胞癌(HCC)的抗肿瘤药物NGR—hTNF罕见病药物身份.此项决定基于欧洲医药评价署(EMEA)罕见病医疗产品委员会的肯定意见.NGR—hTNF还因相同适应证被FDA授予罕见病药物身份.代号为NGR008,有40位患者参与的研究该化合物单独给约治疗肝癌的Ⅱ期临床试验的主要结果显示患者的中位存活...
Phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM)Phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM)Background: NGR-hTNF is a ...
NGR-hTNF is a vascular targeting agent that consists of a modified form of human TNF-α fused with an NGR peptide. The NGR peptide moiety of the compound acts by selectively targeting blood vessels, where TNF is released, resulting in the destruction of the tumor's blood supply and subseque...
FULL PAPER British Journal of Cancer (2013) 109, 360–369 | doi: 10.1038/bjc.2013.347 Keywords: tumour targeting; NGR-hTNF; vascular targeting; angiogenesis; bone marrow-derived cells NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-...
1976 NGRhTNF is a vascular targeting agent in phase II clinical development exploiting a tumor homing peptide (C NGR CG) selectively binding angiogenic vessels in solid tumors, where NGRhTNF specific binding relies on dynamic interactions with TNF-receptors and aminopeptidase N (CD13). Asparagine ...
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy[J]. Eur J Cancer, 2010, 46(15): 2 746-2 752. Full-Text Contact Us service@oalib.com QQ:3279437679 WhatsApp +8615387084133 ...
Dynamic contrast enhanced MRI of solid tumors and healthy tissue during treatment with NGR-TNF, a novel vascular targeting agentvan Laarhoven, Hvan Asten, JDesar, IRizzardi, GBordignon, CPunt, Cvan Herpen, CHeerschap, A
文献报道,将NGR多肽与肿瘤坏死因子相连接,可以将药物带入肿瘤血管,NGR-TNF的抗肿瘤效果比单独使用TNF强30倍[14,17]。Pastorino等[18]将NGR连接到包载有多柔比星的脂质体上,并将该脂质体注射入以常位神经细胞瘤细胞为模型的免疫缺陷性小鼠体内,结果发现与普通脂质体相比,NGR多肽修饰的脂质体在肿瘤部位的积聚提高...
9g, h), TNF-α (Fig. 9i), and IL-6 (Fig. 9j), but no change in the transcription of the CCL2 was found (Fig. 9k). NEP1-40 infusion also promoted the expression of anti-inflammatory cytokines including Arg1 (Fig. 9l), Fizz1 (Fig. 9m), Ym1 (Fig. 9n), cd206 (Fig. 9...
van Laarhoven HW, Fiedler W et al (2010) Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res 16(4):1315–1323 Article PubMed Google Sc...